Harnessing the immune system in acute myeloid leukaemia

Critical Reviews in Oncology/Hematology

Volumn 103, Issue , 2016, Pages 62-77

  Austin, Rebecca ^a   Smyth, Mark J ^a,b   Lane, Steven W ^a,b,c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Acute myeloid leukaemia; Cancer immunosurveillance; Immune checkpoints; Immune suppression; Immunoediting; Immunotherapy; Neo antigens

Indexed keywords

CANCER VACCINE; CD123 ANTIGEN; CD135 ANTIGEN; CD137 ANTIGEN; CD200 ANTIGEN; CD33 ANTIGEN; CD48 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA METHYLTRANSFERASE 3A; DOXORUBICIN; ECALECTIN; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR BETA; IPILIMUMAB; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUCIN 3; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; PROGRAMMED DEATH 1 LIGAND 1; RAS PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR EZH2; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; CYTOKINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CYTOGENETICS; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; IMMUNOSURVEILLANCE; MELANOMA; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE; ACUTE MYELOID LEUKEMIA; ANIMAL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY;

ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; CYTOKINES; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; T-LYMPHOCYTES;

EID: 84969927165     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.04.020     Document Type: Review

References (258)

1. Alatrash G., Molldrem J.J. Vaccines as consolidation therapy for myeloid leukemia. Expert Rev. Hematol. 2011, 4(1):37-50.
2. Alexandrov L.B., et al. Signatures of mutational processes in human cancer. Nature 2013, 500(7463):415-421.
3. Anguille S., et al. Interferon-[alpha] in acute myeloid leukemia: an old drug revisited. Leukemia 2011, 25:739-748.
4. Anguille S., Van Tendeloo V.F., Berneman Z.N. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012, 26(10):2186-2196.
5. Cancer Genome Atlas Research Network Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013, 368(22):2059-2074.
6. PD-L1 upregulation drives escape from anti-CTLA4 and radiation therapy. Cancer Discov. 2015, 5(5):OF13.
7. Ansell S.M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New Engl. J. Med. 2015, 372(4):311-319.
8. Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015, 125(22):3393-3400.
9. Armstrong T.D., et al. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(13):6886-6891.
10. Aurelius J., et al. Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis. Blood 2012, 119(24):5832-5837.
11. Bachireddy P., et al. Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat. Rev. Cancer 2015, 15(4):201-215.
12. Baer M.R., et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001, 97(11):3574-3580.
13. Baessler T., et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res. 2009, 69:1037-1045.
14. Baessler T., et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010, 115:3058-3069.
15. Baragano Raneros A., et al. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia. Genes Immun. 2014.
16. Barclay A.N., Brown M.H. The SIRP family of receptors and immune regulation. Nat. Rev. Immunol. 2006, 6(6):457-464.
17. Behl D., et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006, 20(1):29-34.
18. Berger R., et al. Phase I safety and pharmacokinetic study of CT-011: a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 2008, 14(10):3044-3051.
19. Berlin C., et al. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia 2015, 29(3):647-659.
20. Berneman Z.N., et al. Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis. Br. J. Haematol. 2010, 149:152-155.
21. Berrien-Elliott M.M., et al. Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. Cancer Res. 2013, 73(2):605-616.
22. Berthon C., et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol. Immunother. 2010, 59(12):1839-1849.
23. Bleakley M., Riddell S.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat. Rev. Cancer 2004, 4(5):371-380.
24. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3(7):730-737.
25. Bourhis J.-H., et al. Repeated dosing of anti-KIR (IPH2101) as maintenance therapy in ederly patients with acute myeloid leukemia. Blood 2013, 122(21):2696.
26. Brackertz B., et al. FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes. Blood Cancer J. 2011, 1(3):18.
27. Brentjens R.J., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118(18):4817-4828.
28. Brouwer R.E., et al. Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum. Immunol. 2002, 63(3):200-210.
29. Brown S.D., et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014, 24(5):743-750.
30. Brune M., et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006, 108(1):88-96.
31. Bullinger L., et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. New Engl. J. Med. 2004, 350(16):1605-1616.
32. Buyse M., et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood 2011, 117(26):7007-7013.
33. Cescon D.W., Haibe-Kains B., Mak T.W. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc. Natl. Acad. Sci. U. S. A. 2015, 112(9):2841-2846.
34. Champsaur M., Lanier L.L. Effect of NKG2D ligand expression on host immune responses. Immunol. Rev. 2010, 235(1):267-285.
35. Chamuleau M.E., et al. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica 2008, 93(12):1894-1898.
36. Chamuleau M.E., et al. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2. Leuk. Res. 2011, 35:741-749.
37. Chan C.J., et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat. Immunol. 2014, 15(5):431-438.
38. Chapuis A.G., et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci. Transl. Med. 2013, 5(174):174ra27.
39. Chen X., et al. Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. Cancer Biol. Ther. 2008, 7(5):622-627.
40. Childs R.W., Carlsten M. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat. Rev. Drug Discov. 2015, 14(7):487-498.
41. Choudhury B.A., et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 1999, 93(3):780-786.
42. Cignetti A., et al. CD34+ acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood 1999, 94(6):2048-2055.
43. Cobbold M., et al. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci. Transl. Med. 2013, 5(203):203ra125.
44. Coles S.J., et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 2011, 25:792-799.
45. Cooper M.A., et al. Cytokine-induced memory-like natural killer cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(6):1915-1919.
46. Corm S., et al. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma. Leuk. Res. 2009, 33(3):490-494.
47. Costello R.T., et al. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Eur. J. Immunol. 1998, 28(1):90-103.
48. Costello R.T., et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002, 99:3661-3667.
49. Curti A., et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia 2007, 21(2):353-355.
50. Curti A., et al. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood 2009, 113(11):2394-2401.
51. Döhner H., Weisdorf D.J., Bloomfield C.D. Acute myeloid leukemia. New Engl. J. Med. 2015, 373(12):1136-1152.
52. Davila M.L., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 2014, 6(224):224ra25.
53. De Rossi G., et al. Immunological definition of acute promyelocytic leukemia (FAB M3): a study of 39 cases. Eur. J. Haematol. 1990, 45(3):168-171.
54. Della Chiesa M., et al. The tryptophan catabolite l-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 2006, 108(13):4118-4125.
55. Dohner K., et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005, 106(12):3740-3746.
56. Dohner H., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115(3):453-474.
57. Dulphy N., et al. Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis. Br. J. Haematol. 2014, 165(5):722-725.
58. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 2004, 22:329-360.
59. Ebata K., et al. Immature NK cells suppress dendritic cell functions during the development of leukemia in a mouse model. J. Immunol. 2006, 176:4113-4124.
60. Egen J.G., Kuhns M.S., Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 2002, 3(7):611-618.
61. El Kholy N.M., et al. Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells. Med. Oncol. 2011, 28(1):270-278.
62. Elias S., et al. Immune evasion by oncogenic proteins of acute myeloid leukemia. Blood 2014, 123(10):1535-1543.
63. Fallarino F., et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 2006, 176(11):6752-6761.
64. Fauriat C., et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 2007, 109:323-330.
65. Fevery S., et al. CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. Leukemia 2007, 21(7):1451-1459.
66. Folgiero V., et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget 2014, 5(8):2052-2064.
67. Francisco L.M., et al. PD-L1 regulates the development: maintenance, and function of induced regulatory T cells. J. Exp. Med. 2009, 206(13):3015-3029.
68. Gal H., et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006, 20(12):2147-2154.
69. Galli S., et al. CD47 protein expression in acute myeloid leukemia: a tissue microarray-based analysis. Leuk. Res. 2015, 39(7):749-756.
70. Gambacorti-Passerini C., et al. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood 1993, 81(5):1369-1375.
71. Gao L., Yu S., Zhang X. Hypothesis: Tim-3/Galectin-9, a new pathway for leukemia stem cells survival by promoting expansion of myeloid-derived suppressor cells and differentiating into tumor-associated macrophages. Cell Biochem. Biophys. 2014, 70(1):273-277.
72. Gertner-Dardenne J., et al. Human Vgamma9Vdelta2 T cells specifically recognize and kill acute myeloid leukemic blasts. J. Immunol. 2012, 188(9):4701-4708.
73. Gill S., et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 2014, 123(15):2343-2354.
74. Gleason M.K., et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 2012, 119(13):3064-3072.
75. Gorczynski R.M., Lee L., Boudakov I. Augmented induction of CD4 + CD25+ treg using monoclonal antibodies to CD200R. Transplantation 2005, 79(9):1180-1183.
76. Goswami M., et al. Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. Leukemia 2014, 28(5):1167-1170.
77. Graf C., et al. A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. Blood 2007, 109(7):2985-2988.
78. Green M.R., et al. Integrative analysis reveals selective 9p24.1 amplification: increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010, 116(17):3268-3277.
79. Greiner J., et al. Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin. Cancer Res. 2008, 14(22):7161-7166.
80. Greiner J., et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood 2012, 120(6):1282-1289.
81. Grignani F., et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993, 74(3):423-431.
82. Grimwade D., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116(3):354-365.
83. Gros F., et al. Soluble HLA-G molecules are increased during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia 2006, 8(3):223-230.
84. Grossmann V., et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012, 120(15):2963-2972.
85. Grosso J.F., et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J. Clin. Invest. 2007, 117(11):3383-3392.
86. Grupp S.A., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. New Engl. J. Med. 2013, 368(16):1509-1518.
87. Hadrup S., Donia M., thor Straten P. Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron. 2013, 6(2):123-133.
88. Hallett W.H., et al. Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses. Biol. Blood Marrow Transplant. 2008, 14:1088-1099.
89. Hamid O., et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. New Engl. J. Med. 2013, 369(2):134-144.
90. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
91. Hausler S.F., et al. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol. Immunother. 2011, 60(10):1405-1418.
92. Heiblig M., et al. Adoptive immunotherapy for acute leukemia: new insights in chimeric antigen receptors. World J. Stem Cells 2015, 7(7):1022-1038.
93. Hemon P., et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J. Immunol. 2011, 186(9):5173-5183.
94. Hentschel N., et al. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma. Eur. J. Haematol. 2006, 77(2):91-101.
95. Hodi F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl. J. Med. 2010, 363(8):711-723.
96. Hoek R.M., et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000, 290(5497):1768-1771.
97. Hosen N., et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(26):11008-11013.
98. Huard B., et al. Cellular expression and tissue distribution of the human LAG-3-encoded protein: an MHC class II ligand. Immunogenetics 1994, 39(3):213-217.
99. Jan M., et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3: a human acute myeloid leukemia stem cell marker. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(12):5009-5014.
100. Kageshita T., et al. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am. J. Pathol. 1999, 154(3):745-754.
101. Kalos M., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 2011, 3(95):3002842.
102. Kaplan J.B., Grischenko M., Giles F.J. Blinatumomab for the treatment of acute lymphoblastic leukemia. Invest. New Drugs 2015, 33(6):1271-1279.
103. Keilholz U., et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009, 113(26):6541-6548.
104. Kelderman S., Schumacher T.N., Haanen J.B. Acquired and intrinsic resistance in cancer immunotherapy. Mol. Oncol. 2014, 8(6):1132-1139.
105. Kikushige Y., Akashi K. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia. Ann. N.Y. Acad. Sci. 2012, 1266(1):118-123.
106. Kikushige Y., et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010, 7(6):708-717.
107. Kochan G., et al. Role of non-classical MHC class I molecules in cancer immunosuppression. Oncoimmunology 2013, 2(11):e26491.
108. Kochenderfer J.N., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116(20):4099-4102.
109. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
110. Kong Y., et al. PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J. 2015, 5:pe330.
111. Konjevic G., et al. Novel aspects of in vitro IL-2 or IFN-alpha enhanced NK cytotoxicity of healthy individuals based on NKG2D and CD161 NK cell receptor induction. Biomed. Pharmacother. 2010, 64:663-671.
112. Kretz-Rommel A., et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J. Immunol. 2007, 178(9):5595-5605.
113. Krivtsov A.V., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442(7104):818-822.
114. Kronig H., et al. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur. J. Haematol. 2014, 92(3):195-203.
115. Krupka C., et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014, 123(3):356-365.
116. Krupka C., et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia 2015.
117. Kuball J., et al. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunol. Immunother. 2011, 60(2):161-171.
118. Kumar C.C. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2011, 2(2):95-107.
119. LaBelle J.L., et al. Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia. Blood 2002, 99(6):2146-2153.
120. Lane S.W., Gilliland D.G. Leukemia stem cells. Semin. Cancer Biol. 2010, 20(2):71-76.
121. Laurent S., et al. CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis. Br. J. Haematol. 2007, 136(4):597-608.
122. Le Dieu R., et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 2009, 114(18):3909-3916.
123. Lee J.J., et al. Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia. Leuk. Res. 2001, 25(12):1067-1073.
124. Lee G.K., et al. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 2002, 107(4):452-460.
125. Lee S.-K., et al. IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells. J. Dermatol. Sci. 2005, 40(2):95-103.
126. Lee J.Y., et al. Restoration of natural killer cell cytotoxicity by VEGFR-3 inhibition in myelogenous leukemia. Cancer Lett. 2014, 354(2):281-289.
127. Li C., et al. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification. Int. J. Clin. Exp. Pathol. 2014, 7(10):6880-6888.
128. Lindsley R.C., et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 2015, 125(9):1367-1376.
129. Lion E., et al. Natural killer cell immune escape in acute myeloid leukemia. Leukemia 2012, 26(9):2019-2026.
130. Liu X., et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010, 115(17):3520-3530.
131. Liu J., et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One 2015, 10(9):e0137345.
132. Long E.O., et al. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 2013, 31:227-258.
133. Lowdell M.W., et al. The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia. Bone Marrow Transplant. 1997, 19:891-897.
134. Lowdell M.W., et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br. J. Haematol. 2002, 117:821-827.
135. Mérino D., et al. TRAIL in cancer therapy: present and future challenges. Expert Opin. Ther. Targets 2007, 11(10):1299-1314.
136. Majeti R., et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(9):3396-3401.
137. Majeti R., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138(2):286-299.
138. Makita M., et al. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes. Leukemia 2002, 16(12):2400-2407.
139. Mardiros A., et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 2013, 122(18):3138-3148.
140. Markey K.A., MacDonald K.P., Hill G.R. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood 2014, 124(3):354-362.
141. Martner A., et al. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia. Expert Rev. Hematol. 2010, 3(4):381-391.
142. Masuda K., et al. Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts. Cancer Sci. 2007, 98(1):102-108.
143. Matulonis U., et al. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 1996, 156(3):1126-1131.
144. Miraki-Moud F., et al. Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(33):13576-13581.
145. Mitelman F., Johansson B., Mertens F. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer 2015, Available from:. http://cgap.nci.nih.gov/Chromosomes/Mitelman.
146. Mittal D., et al. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr. Opin. Immunol. 2014, 27:16-25.
147. Mizuno S., et al. Aberrant expression of HLA-G antigen in interferon gamma-stimulated acute myelogenous leukaemia. Br. J. Haematol. 2000, 111(1):280-282.
148. Muller C.I., et al. Hematologic and molecular spontaneous remission following sepsis in acute monoblastic leukemia with translocation (9;11): a case report and review of the literature. Eur. J. Haematol. 2004, 73(1):62-66.
149. Mussai F., et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood 2013, 122(5):749-758.
150. Nakata J., et al. In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity. Leukemia 2014, 28(6):1316-1325.
151. Nanbakhsh A., et al. c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis. Blood 2014, 123(23):3585-3595.
152. Ngiow S.F., et al. A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1. Cancer Res. 2015, 75(18):3800-3811.
153. Nocentini G., et al. Pharmacological modulation of GITRL/GITR system: therapeutic perspectives. Br. J. Pharmacol. 2012, 165(7):2089-2099.
154. North J., et al. Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J. Immunol. 2007, 178(1):85-94.
155. Nowbakht P., et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005, 105:3615-3622.
156. Ochsenreither S., et al. Wilms Tumor Protein 1 (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow. J. Immunother. 2011, 34(1):85-91.
157. Ochsenreither S., et al. Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3beta sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer Immunol. Immunother. 2012, 61(3):313-322.
158. Okazaki T., et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 2013, 14(12):1212-1218.
159. Osman Y., et al. Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy. J. Exp. Clin. Cancer Res. 1999, 18(4):485-492.
160. Pabst T., et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat. Med. 2001, 7(4):444-451.
161. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12(4):252-264.
162. Passegué E., et al. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(Suppl. 1):11842-11849.
163. Pegram H.J., et al. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?. Immunotherapy 2015, 7(5):545-561.
164. Pende D., et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005, 105:2066-2073.
165. Pende D., et al. PVR (CD155) and nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol. Immunol. 2005, 42:463-469.
166. Peter M.E., et al. The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 2015, 22(4):549-559.
167. Pizzitola I., et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 2014, 28(8):1596-1605.
168. Pizzolo G., et al. Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission. Br. J. Cancer 1988, 58(3):368-372.
169. Polakova K., et al. Binding analysis of HLA-G specific antibodies to hematopoietic cells isolated from leukemia patients. Neoplasma 2003, 50(5):331-338.
170. Pross H.F., Lotzova E. Role of natural killer cells in cancer. Nat. Immun. 1993, 12:279-292.
171. Rajasagi M., et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 2014, 124(3):453-462.
172. Ramirez-Montagut T., et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J. Immunol. 2006, 176(11):6434-6442.
173. Raulet D.H., Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat. Rev. Immunol. 2009, 9(8):568-580.
174. Re F., et al. Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage. Exp. Hematol. 2002, 30(2):126-134.
175. Rezvani K., et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008, 111(1):236-242.
176. Riccioni R., et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 2005, 90:612-624.
177. Riether C., Schurch C.M., Ochsenbein A.F. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ. 2015, 22(2):187-198.
178. Ritchie D.S., et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol. Ther. 2013, 21(11):2122-2129.
179. Robb R.J., et al. Type I-IFNs control GVHD and GVL responses after transplantation. Blood 2011, 118(12):3399-3409.
180. Robert C., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384(9948):1109-1117.
181. Robert C., et al. Nivolumab in previously untreated melanoma without BRAF mutation. New Engl. J. Med. 2015, 372(4):320-330.
182. Romagne F., et al. Preclinical characterization of 1-7F9: a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009, 114(13):2667-2677.
183. Romee R., Leong J.W., Fehniger T.A. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) 2014, 2014:205796.
184. Rooney M.S., et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015, 160(1-2):48-61.
185. Ruggeri L., et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol. Dis. 2008, 40(1):84-90.
186. Rutledge W.C., et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin. Cancer Res. 2013, 19(18):4951-4960.
187. Saito Y., et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci. Transl. Med. 2010, 2(17):17ra9.
188. Salih H.R., et al. Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies. J. Immunol. 2001, 167(7):4059-4066.
189. Salih H.R., et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003, 102:1389-1396.
190. Salih H.R., et al. The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp. Hematol. 2006, 34(7):888-894.
191. Sanchez-Correa B., et al. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol. Immunother. 2011, 60(8):1195-1205.
192. Sanchez-Correa B., et al. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol. Cell Biol. 2012, 90(1):109-115.
193. Saudemont A., Quesnel B. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood 2004, 104(7):2124-2133.
194. Scheibenbogen C., et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002, 100(6):2132-2137.
195. Scheich F., et al. The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens. Blood 2007, 110(7):2556-2560.
196. Schlenk R.F., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New Engl. J. Med. 2008, 358(18):1909-1918.
197. Scholl S., et al. Flt3-ITD mutations can generate leukaemia specific neoepitopes: potential role for immunotherapeutic approaches. Leuk. Lymphoma 2006, 47(2):307-312.
198. Scholl C., Gilliland D.G., Froehling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin. Oncol. 2008, 35(4):336-345.
199. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
200. Sehgal A., Whiteside T.L., Boyiadzis M. Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opin. Biol. Ther. 2015, 15(8):1191-1203.
201. Shenghui Z., et al. Elevated frequencies of CD4(+) CD25(+) CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int. J. Cancer 2011, 129(6):1373-1381.
202. Shih A.H., et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 2012, 12(9):599-612.
203. Simpson T.R., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 2013, 210(9):1695-1710.
204. Smits E.L., Anguille S., Berneman Z.N. Interferon alpha may be back on track to treat acute myeloid leukemia. Oncoimmunology 2013, 2(4):e23619.
205. Smyth M.J., Dunn G.P., Schreiber R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 2006, 90:1-50.
206. Snyder A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. New Engl. J. Med. 2014, 371(23):2189-2199.
207. Soriani A., et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009, 113(15):3503-3511.
208. Stringaris K., et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica 2014, 99(5):836-847.
209. Sugiyama H. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. Jpn. J. Clin. Oncol. 2010, 40(5):377-387.
210. Swann J.B., Smyth M.J. Immune surveillance of tumors. J. Clin. Invest. 2007, 117(5):1137-1146.
211. Swann J.B., et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 2007, 178(12):7540-7549.
212. Swerdlow S.H., Campo E., Harris N.L. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, IARC, Lyon, France. E. Campo, S.H. Swerdlow, N.L. Harris (Eds.).
213. Szczepanski M.J., et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin. Cancer Res. 2009, 15:3325-3332.
214. Szczepanski M.J., et al. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol. Immunother. 2010, 59:73-79.
215. Tajima F., et al. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia 1996, 10:478-482.
216. Tamura H., et al. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin. Cancer Res. 2005, 11(16):5708-5717.
217. Tasian S.K., Gardner R.A. CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther. Adv. Hematol. 2015, 6(5):228-241.
218. Teague R., Kline J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J. ImmunoTher. Cancer 2013, 1(1):13.
219. Tenen D.G. Disruption of differentiation in human cancer: AML shows the way. Nat. Rev. Cancer 2003, 3(2):89-101.
220. The Cancer Genome Atlas Research Network, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Engl. J. Med. 2013, 368(22):2059-2074.
221. Tonks A., et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007, 21(3):566-568.
222. Tonks A., et al. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 2007, 21(12):2495-2505.
223. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl. J. Med. 2012, 366(26):2443-2454.
224. Tratkiewicz J.A., Szer J. Loss of natural killer activity as an indicator of relapse in acute leukaemia. Clin. Exp. Immunol. 1990, 80(2):241-246.
225. Tseng D., et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(27):11103-11108.
226. Tsuboi A., et al. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk. Res. 1999, 23(5):499-505.
227. Twyman-Saint Victor C., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520(7547):373-377.
228. Uttenthal B., et al. Wilms' tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br. J. Haematol. 2014, 164(3):366-375.
229. Valk P.J., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 2004, 350(16):1617-1628.
230. Van Driessche A., Berneman Z.N., Van Tendeloo V.F. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist 2012, 17(2):250-259.
231. Vardiman J.W., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(5):937-951.
232. Verheyden S., Demanet C. Susceptibility to myeloid and lymphoid leukemia is mediated by distinct inhibitory KIR-HLA ligand interactions. Leukemia 2006, 20(8):1437-1438.
233. Verheyden S., Demanet C. NK cell receptors and their ligands in leukemia. Leukemia 2008, 22:249-257.
234. Verheyden S., Bernier M., Demanet C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 2004, 18:2002-2007.
235. Vey N., et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012, 120(22):4317-4323.
236. Vogelstein B., et al. Cancer genome landscapes. Science 2013, 339(6127):1546-1558.
237. Vollmer M., et al. Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia. Br. J. Haematol. 2003, 120(6):1000-1008.
238. Walter R.B. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia. Expert Rev. Hematol. 2014, 7(June (3)):317-319. Epub 2014 March 11. 10.1586/17474086.2014.896190.
239. Wang X., et al. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur. J. Haematol. 2005, 75:468-476.
240. Wang X., et al. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur. J. Haematol. 2005, 75(6):468-476.
241. Watari K., et al. Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene. FEBS Lett. 2000, 466(2-3):367-371.
242. Wetzler M., et al. HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Leukemia 2001, 15(1):128-133.
243. Wolchok J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. New Engl. J. Med. 2013, 369(2):122-133.
244. Workman C.J., et al. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J. Immunol. 2004, 172(9):5450-5455.
245. Wu J.D., et al. Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin. Cancer Res. 2009, 15(2):632-640.
246. Yan W.H., et al. Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J. Cell. Mol. Med. 2008, 12(3):889-898.
247. Yang L.P., Perry C.M. Histamine dihydrochloride: in the management of acute myeloid leukaemia. Drugs 2011, 71(1):109-122.
248. Yonezawa A., et al. Boosting cancer immunotherapy with anti-CD137 antibody therapy. Clin. Cancer Res. 2015.
249. Yu J., et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 2013, 190(7):3783-3797.
250. Yuda J., et al. TIM-3, a leukemia stem cell marker, plays a role In leukemic transformation through autocrine stimulatory signaling by its ligand, galectin-9. Blood 2013, 122(21):4196.
251. Zhang C., et al. Opposing effect of IFNgamma and IFNalpha on expression of NKG2 receptors: negative regulation of IFNgamma on NK cells. Int. Immunopharmacol. 2005, 5:1057-1067.
252. Zhang L., Gajewski T.F., Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009, 114(8):1545-1552.
253. Zhou Q., et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011, 117(17):4501-4510.
254. Zhou F., Shen Q., Claret F.X. Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia. J. Leukoc. Biol. 2013, 94(3):423-429.
255. de Jonge H.J.M., et al. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 2010, 116(10):1747-1754.
256. van Luijn M.M., et al. Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia. Immunotherapy 2010, 2(1):85-97.
257. van Luijn M.M., et al. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells. Cancer Res. 2011, 71(7):2507-2517.
258. van den Ancker W., et al. High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia. Leuk. Res. 2014, 38(6):691-693.